SKYE vs. MBX, RGNX, TSHA, TRVI, ATYR, TERN, TRML, CYRX, ACB, and ATAI
Should you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include MBX Biosciences (MBX), REGENXBIO (RGNX), Taysha Gene Therapies (TSHA), Trevi Therapeutics (TRVI), Atyr PHARMA (ATYR), Terns Pharmaceuticals (TERN), Tourmaline Bio (TRML), Cryoport (CYRX), Aurora Cannabis (ACB), and Atai Life Sciences (ATAI). These companies are all part of the "pharmaceutical products" industry.
Skye Bioscience vs.
Skye Bioscience (NASDAQ:SKYE) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations.
In the previous week, Skye Bioscience had 9 more articles in the media than MBX Biosciences. MarketBeat recorded 11 mentions for Skye Bioscience and 2 mentions for MBX Biosciences. Skye Bioscience's average media sentiment score of 0.60 beat MBX Biosciences' score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the media.
Skye Bioscience currently has a consensus target price of $18.67, suggesting a potential upside of 643.69%. MBX Biosciences has a consensus target price of $37.25, suggesting a potential upside of 267.36%. Given Skye Bioscience's higher possible upside, analysts plainly believe Skye Bioscience is more favorable than MBX Biosciences.
Skye Bioscience received 8 more outperform votes than MBX Biosciences when rated by MarketBeat users.
21.1% of Skye Bioscience shares are held by institutional investors. 3.0% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
MBX Biosciences' return on equity of 0.00% beat Skye Bioscience's return on equity.
Summary
Skye Bioscience beats MBX Biosciences on 7 of the 9 factors compared between the two stocks.
Get Skye Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skye Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:SKYE) was last updated on 3/4/2025 by MarketBeat.com Staff
Free SKYE Stock Alerts